Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated June 1, 2022, announces a material corporate update regarding the proposed demerger of its Consumer Healthcare business to form a new independent listed company, Haleon plc. The filing details the submission of the Circular and Prospectus to the Financial Conduct Authority (FCA) for approval, with the General Meeting for shareholder approval scheduled for July 6, 2022.
Key Financial Metrics
The filing provides specific financial data for the Consumer Healthcare business (Haleon) but does not report consolidated revenue, profit, or cash flow for GSK plc for the current period.
- Haleon Profit Before Tax: £1,636 million for the year ended December 31, 2021.
- Haleon Gross Assets: £45,023 million as of March 31, 2022.
- Haleon Net Debt (Pro Forma): £10,349 million as of March 31, 2022 (unaudited).
- Pre-Demerger Dividends: GSK expects to receive cash proceeds of more than £7 billion from dividends paid by the joint venture prior to the demerger.
- Revenue Composition (Haleon 2021): Oral Health (28.5%), Pain Relief (23.4%), Digestive Health and Other (20.4%), VMS (15.7%), Respiratory Health (11.9%).
Material Changes and Corporate Structure
The proposed demerger represents the most significant corporate change for GSK in 20 years. Key structural changes include:
- Separation: At least 80% of GSK's 68% holding in the Consumer Healthcare business will be demerged to GSK shareholders.
- Ownership Post-Demerger: GSK shareholders will hold at least 54.5% of Haleon; GSK will retain up to 6%; Pfizer will hold 32%; and Scottish Limited Partnerships (SLPs) will hold 7.5%.
- Strategic Focus: Post-demerger, GSK will focus purely on biopharmaceuticals (vaccines and specialty medicines), while Haleon will operate as a global leader in consumer healthcare.
- Accounting Treatment: The Consumer Healthcare business will be treated as a discontinued operation in GSK's second-quarter 2022 results.
Guidance, Outlook, and Risks
Management Commentary and Outlook:
- GSK Targets: Over the next five years, GSK expects compound annual growth in sales of more than 5% and adjusted operating profit of more than 10% at constant exchange rates (2021 base).
- Haleon Targets: Haleon targets medium-term annual organic revenue growth of 4% to 6% and sustainable moderate adjusted margin expansion on a constant currency basis.
- Share Consolidation: GSK intends to consolidate its shares following the demerger to maintain price consistency and earnings per share comparability.
Risks and Contingencies:
- Conditions Precedent: The demerger is conditional on shareholder approval, regulatory approvals, and final board approval.
- Related Party Transactions: New arrangements with Pfizer (a related party due to its 32% interest) require shareholder approval.
- Forward-Looking Statements: Outlooks assume no material interruptions to supply, no significant geopolitical developments, and no material changes in foreign currency exchange rates or the impact of the COVID-19 pandemic.
Investor Verification Checklist
- Verify the outcome of the General Meeting on July 6, 2022, regarding shareholder approval of the demerger and related party transactions.
- Confirm the admission of Haleon ordinary shares to the London Stock Exchange and NYSE ADS listing on or around July 18, 2022.
- Review the unaudited pro forma financial information for Haleon in the full Prospectus to understand the basis of the £10,349 million net debt figure.
- Monitor the execution of the "Orderly Marketing Agreement" and "Lock-up Deed" which restricts the sale of Haleon shares by GSK and Pfizer until November 2022 or the release of a quarterly update.
- Check the timing of GSK's Q2 2022 results (announced July 27, 2022) to see the financial impact of treating Consumer Healthcare as a discontinued operation.